1. Home
  2. CRTO vs CMPX Comparison

CRTO vs CMPX Comparison

Compare CRTO & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Criteo S.A.

CRTO

Criteo S.A.

HOLD

Current Price

$17.20

Market Cap

980.6M

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$5.23

Market Cap

927.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRTO
CMPX
Founded
2005
2014
Country
France
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
980.6M
927.5M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
CRTO
CMPX
Price
$17.20
$5.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
9
Target Price
$35.90
$14.43
AVG Volume (30 Days)
275.2K
1.7M
Earning Date
05-01-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
38.95
N/A
EPS
2.64
N/A
Revenue
$2,296,692,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.62
$677.91
P/E Ratio
$6.69
N/A
Revenue Growth
27.65
N/A
52 Week Low
$16.15
$1.33
52 Week High
$36.06
$6.88

Technical Indicators

Market Signals
Indicator
CRTO
CMPX
Relative Strength Index (RSI) 40.43 41.55
Support Level $16.15 $4.86
Resistance Level $21.32 $5.86
Average True Range (ATR) 0.71 0.29
MACD -0.04 0.01
Stochastic Oscillator 21.63 36.26

Price Performance

Historical Comparison
CRTO
CMPX

About CRTO Criteo S.A.

Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: